Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
BioAge Labs’ $238 Million Upsized Initial Public Offering
SCYNEXIS’ License Agreement With GSK for Brexafemme
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...